本帖最后由 老马 于 2012-1-13 21:20 编辑
6 s) T5 x& x8 H6 Y% Z; a# A9 |4 Z1 K& ?: u8 Z$ q
爱必妥和阿瓦斯丁的比较
* P+ @6 z) V" Q, J
$ u( o( X7 R8 }% G2 B) H9 u
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
: f7 d, M; `$ U. }7 P8 C
+ e( ~9 C: X! k. r5 }0 y
* i. F/ `" s0 [* v
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 _2 C& S$ q1 `==================================================. v; K( `5 }' k( Q# i
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 F Z( y4 Z7 {* rPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" Z6 H l" e* UResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported., ]* r) o( ?- T0 y7 p& ?
|